LCM
MRNS

Laurion Capital Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Laurion Capital Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-15,377
Closed -$74K – 635
2022
Q2 		$74K Buy
+15,377
New +$93.5K ﹤0.01% 406
2021
Q1 		– Sell
-160,161
Closed -$1.95M – 931
2020
Q4 		$1.95M Buy
+160,161
New +$2.23M 0.02% 345

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return

Laurion Capital Management's MRNS Position: Q3 2022 in Review

Laurion Capital Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2022, closing a stake of 15,377 shares — an estimated $74K sold.

Laurion Capital Management first reported a position in MRNS in Q4 2020 and held it in 2 quarters. The position peaked at $1.95M in Q4 2020. 69 funds tracked by Wall St. Rank hold MRNS as of Q3 2022.

  • Laurion Capital Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2022 after selling out during the quarter.
  • Laurion Capital Management sold 15,377 Marinus Pharmaceuticals, Inc shares in Q3 2022, an estimated $74K.
  • Laurion Capital Management first reported a position in Marinus Pharmaceuticals, Inc in Q4 2020 and held it in 2 quarters.
  • Laurion Capital Management's Marinus Pharmaceuticals, Inc position peaked at $1.95M in Q4 2020.
  • 69 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2022.

Based on Laurion Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.